Subjective well-being and quality of life under atypical antipsychotic treatment A. KarowD. Naber Review 20 April 2002 Pages: 3 - 10
The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia Elisabeth M. WeissRobert M. BilderWolfgang W. Fleischhacker Review 17 April 2002 Pages: 11 - 17
Clinical applications of pharmacogenetics in psychiatry Susan StaddonMaria J. ArranzRobert W. Kerwin Review 25 April 2002 Pages: 18 - 23
Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale L. de HaanM. WeisfeltL. Wouters Original Investigation 05 April 2002 Pages: 24 - 28
Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia Frank-Gerald PajonkRüdiger HolzbachDieter Naber Original Investigation 19 April 2002 Pages: 29 - 36
Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole Svante NybergHans OlssonLars Farde Original Investigation 14 May 2002 Pages: 37 - 41
Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol Johannes TauscherBernd KüfferleSiegfried Kasper Original Investigation 16 May 2002 Pages: 42 - 49
Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes Shingo OnoKazuo MiharaSunao Kaneko Original Investigation 20 April 2002 Pages: 50 - 54
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms Walid Abi-SaabJohn P. SeibylJohn H. Krystal Original Investigation 05 April 2002 Pages: 55 - 62
Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia Norio Yasui-FurukoriTsuyoshi KondoSunao Kaneko Original Investigation 17 April 2002 Pages: 63 - 66
Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype Peeter JaansonToomas MarandiMarja-Liisa Dahl Original Investigation 20 April 2002 Pages: 67 - 73
A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia Paul B. FitzgeraldTimothy L. BrownJ. Kulkarni Original Investigation 05 April 2002 Pages: 74 - 81
Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe Wolfgang W. FleischhackerTom BurnsEuropean Group for Research in Schizophrenia Original Investigation 12 April 2002 Pages: 82 - 84
Risperidone may induce mania Y. GüzelcanL. de HaanW. F. Scholte Case Report 05 April 2002 Pages: 85 - 86
Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder Frits JonkersLieuwe de Haan Case Report 04 April 2002 Pages: 87 - 88
Clozapine is more efficacious for tongue dystonia than olanzapine Philippe ConusDaniele ZullinoPierre Baumann Case Report 05 April 2002 Pages: 89 - 89
Second generation antipsychotics W. Wolfgang Fleischhacker Letters to the Editors 25 April 2002 Pages: 90 - 91
New study designs for new antipsychotics R. S. Kahn Letter to the Editors 22 March 2002 Pages: 92 - 92
Prolactin secretion is not a core dimension of “atypicality” Gerhard GründerOtto Benkert Letter to the editors 05 March 2002 Pages: 93 - 93
Olanzapine-induced galactorrhea Rasmus W. LichtTorben ArngrimHilmar Christensen Letters to the Editors 22 March 2002 Pages: 94 - 95
